Development of heart failure was linked to the greatest risk of death among type 2 diabetics with cardiovascular conditions, reports a new study.

"With the emergence of novel treatments such as SGLT2 inhibitors and GLP-1 receptor antagonist medications for Type 2 diabetes, some of which are proven to reduce cardiovascular disease risk, clinicians are able to focus on cardiovascular disease and heart failure prevention in patients with Type 2 diabetes," said Bochra Zareini, M.D., Ph.D., principal investigator and research fellow at Herlev Gentofte University Hospital in Copenhagen, Denmark.
"Our study highlights which subgroups of patients need and could benefit most from targeted risk evaluation, prevention, and treatment."
The study identified patients who were age 18 and older without prior heart and kidney disease and were newly diagnosed with Type 2 diabetes nationwide, Danish health registers. From 1998 to 2015, more than 153,000 patients were followed for approximately ten years. During the median follow-up of 9.7 years, 45.1% of the patients (69,201) were diagnosed with a cardiovascular or kidney disease. Researchers estimated the five-year risk of death, the five-year risk ratios and the decrease in lifespan within five years associated with the development of any cardiovascular disease, such as heart failure, ischemic heart disease, stroke, peripheral artery disease and chronic kidney disease.
Researchers found:
- heart failure in combination with any other diagnosis in the study was associated with the greatest risk of death and highest decrease in lifespan compared to combinations of other cardiovascular diseases and Type 2 diabetes;
- the five-year risk ratio of death associated with heart failure development after Type 2 diabetes diagnosis was three times higher in patients with diabetes than in patients without diabetes;
- risks were elevated regardless of when the patient developed the cardiovascular disease after being diagnosed with Type 2 diabetes; and
- the elevated risk of death was present in all subgroups based on the patient's age, gender and presence of other conditions.
MEDINDIA














